CorMedix (CRMD) Stock Forecast & Price Target

Cormedix Inc. is poised for future growth, particularly through the expansion of its DefenCath product into total parenteral nutrition (TPN), which enhances both its eligible patient base and achievable net pricing. The company anticipates substantial improvements in DefenCath pricing, potentially increasing three to five times over projections for the second half of 2026, and has set a robust sales guidance of $100 million to $140 million for 2027. Additionally, operational trends show strong utilization and patient growth, with multiple upside drivers identified, including increased patient utilization and enhanced reimbursement opportunities, further reinforcing the positive outlook for the company’s financial performance.

Cormedix Inc. has issued revenue guidance for 2026 that falls significantly below both internal estimates and consensus expectations, reflecting a projected top-line of $300 million to $320 million and DefenCath sales of $150 million to $170 million, which are markedly lower than prior forecasts. The anticipated transition from TDAPA reimbursement to a standard post-TDAPA Add-On Adjustment after July 1, 2026, is expected to substantially reduce revenue and net pricing for DefenCath, particularly in the latter half of the year. Furthermore, the company's reliance on DefenCath sales, which may face increased competition from generics like Heparin, adds additional downside risk to the financial outlook.